Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-Label Study of MEDI4736 With or Without Tremelimumab in Advanced Solid Tumors
jRCT2080222260Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2013
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in Nonhematologic neoplasms, biliary cancer, Esophageal Squamous Cell Carcinoma (ESCC) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of MEDI4736 ± tremelimumab and Pharmacokinetics of MEDI4736 ± tremelimumab. Started Oct 2013; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Nonhematologic neoplasmsbiliary cancerEsophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080222260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222260.